Among patients with advanced gastric and GEJ cancer, or esophageal adenocarcinoma, treatment with first-line Opdivo and chemo demonstrated deep responses.

CheckMate 649 trial showed sustained efficacy with frontline nivolumab plus chemotherapy vs chemotherapy alone in patients with gastric cancers.

The FDA has accepted a BLA for treatment with RP1 in combination with Opdivo for patients with advanced melanoma who have ...

Replimune Group, Inc. REPL announced that the FDA has accepted the biologics license application (BLA) for its lead pipeline ...

In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Replimune Group (REPL – Research Report), with a price ...

EconoTimes is a global, independent publication that delivers comprehensive news, analysis, and insights on the economy, finance, and markets. Based in Korea, we offer a unique perspective on global ...

The US oncology biosimilar market has rapidly evolved since its launch in 2017, driven by steep price discounts, payer ...

EconoTimes is a global, independent publication that delivers comprehensive news, analysis, and insights on the economy, finance, and markets. Based in Korea, we offer a unique perspective on global ...

An FDA committee’s September 2024 vote to limit the use of Merck’s Keytruda and BMS’ Opdivo in stomach and esophageal cancers ...

(This Dec. 27 story has been corrected to say Opdivo Qvantig has been approved to treat most previously approved tumor indications, not all previously approved tumor indications, in paragraph 5) By ...

Opdivo Qvantig combines nivolumab, a programmed death receptor-1 (PD-1)-blocking antibody, with hyaluronidase, an endoglycosidase that increases the permeability of the SC tissue. Opdivo was ...

FRIDAY, Jan. 3, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use for most previously ...